Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka-shi, Osaka, 5418567, Japan.
Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Ann Hematol. 2021 Nov;100(11):2717-2725. doi: 10.1007/s00277-021-04631-8. Epub 2021 Sep 3.
We evaluated the survival patterns for acute myeloid leukemia (AML) patients registered in the Osaka Cancer Registry from 1975 to 2017. During this period, 9706 patients were diagnosed with AML, with a median age of 60 years (range, 0-100). Patients were grouped by age (≤ 20, 21-40, 41-60, 61-70, and ≥ 71) and the year of their diagnosis (1975-1989, 1990-2001, 2002-2010, and 2011-2017). The overall survival (OS) rates of patients of ≤ 60 years of age improved significantly from the period 1975-1989 up to 1990-2001. However, there was a stagnation from 2002-2010 to 2011-2017. In terms of non-acute promyelocytic leukemia patients of > 60 years of age, the improvement of OS was limited during a very long period. In conclusion, the clinical outcome of patients with AML dramatically improved from 1975 to 2001. However, our dataset revealed stagnation in the improvement since 2002. Novel treatment options are needed to further improve the survival of elderly patients.
我们评估了 1975 年至 2017 年期间在大阪癌症登记处登记的急性髓细胞白血病 (AML) 患者的生存模式。在此期间,9706 名患者被诊断为 AML,中位年龄为 60 岁(范围 0-100 岁)。患者按年龄(≤20 岁、21-40 岁、41-60 岁、61-70 岁和≥71 岁)和诊断年份(1975-1989 年、1990-2001 年、2002-2010 年和 2011-2017 年)进行分组。≤60 岁患者的总生存率(OS)从 1975-1989 年显著提高到 1990-2001 年。然而,从 2002-2010 年到 2011-2017 年,这一趋势停滞不前。对于年龄>60 岁的非急性早幼粒细胞白血病患者,OS 的改善在很长一段时间内是有限的。总之,从 1975 年到 2001 年,AML 患者的临床预后显著改善。然而,我们的数据显示,自 2002 年以来,这一改善趋势已经停滞。需要新的治疗选择来进一步提高老年患者的生存率。